Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company completes sale and installation to one of the largest private molecular diagnostics labs in Ghana Company completes sale and installation to one of the largest private molecular diagnostics labs in Ghana

Co-Diagnostics, Inc. Continues to Execute on International Expansion

Vector Smart™ ZDC multiplex PCR test to aid prevention of tropical disease proliferation in the US and abroad Vector Smart™ ZDC multiplex PCR test to aid prevention of tropical disease proliferation in the US and abroad

Co-Diagnostics, Inc. Adds to Menu of Molecular Vector Control Products

Company will host booth to introduce and promote mosquito abatement products to midwestern states in Tulsa, OK on Sept 19-20 Company will host booth to introduce and promote mosquito abatement products to midwestern states in Tulsa, OK on Sept 19-20

Co-Diagnostics, Inc. to Launch Vector Control Products into Midwest US at OPMA Conference

Salt Lake City, Utah, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be featured as a presenting company at the 21st Annual Rodman and Renshaw Global Investment Conference on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City.

Co-Diagnostics, Inc. to Present at 21st Annual Rodman & Renshaw Global Investment Conference Sept 8-10, 2019

Event to include demos and training for distributors and end-users of Company’s products Event to include demos and training for distributors and end-users of Company’s products

Co-Diagnostics, Inc. to Host 2nd Semiannual Distributor Conference on Sept 10-12

Co-Diagnostics, Inc. (NASDAQ: CODX) shared positive results of a study to detect cancer mutations using its patented CoPrimer technology, with applications in liquid biopsy and companion diagnostic tests.

Thursday's Big Winner: Co-Diagnostics

News for Co-Diagnostics Stock (CODX)